APA (7th ed.) Citation

Ling Gao, Ikuo Yamamiya, Mark Pinti, Juan Carlos Rondon, Thomas Marbury, Gareth Tomlinson, . . . Volker Wacheck. (2023). A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Wiley.

Chicago Style (17th ed.) Citation

Ling Gao, Ikuo Yamamiya, Mark Pinti, Juan Carlos Rondon, Thomas Marbury, Gareth Tomlinson, Lukas Makris, Nanae Hangai, and Volker Wacheck. A Phase I, Open‐label, Single‐dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Futibatinib. Wiley, 2023.

MLA (9th ed.) Citation

Ling Gao, et al. A Phase I, Open‐label, Single‐dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Futibatinib. Wiley, 2023.